BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28926265)

  • 21. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
    Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
    J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
    Qi C; Zhang QH; Li JX
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models.
    Arzuman L; Beale P; Yu JQ; Huq F
    Anticancer Res; 2015 May; 35(5):2783-94. PubMed ID: 25964558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers.
    Bhosale SS; Mandal A; Hou C; McCorkle JR; Schweer D; Hill KS; Subramanian V; Kolesar JM; Tsodikov OV; Rohr J
    ChemMedChem; 2023 Feb; 18(3):e202200368. PubMed ID: 36342449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
    Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
    BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer.
    Juvekar AS; Adwankar MK; Tongaonkar HB
    Cancer Biother Radiopharm; 2000 Jun; 15(3):295-300. PubMed ID: 10941537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    van Zyl B; Tang D; Bowden NA
    Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Calo CA; Smith BQ; Dorayappan KDP; Saini U; Lightfoot M; Wagner V; Kalaiyarasan D; Cosgrove C; Wang QE; Maxwell GL; Kálai T; Kuppusamy P; Cohn DE; Selvendiran K
    Gynecol Oncol; 2022 Jan; 164(1):136-145. PubMed ID: 34756749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer.
    Bruckman MA; Czapar AE; VanMeter A; Randolph LN; Steinmetz NF
    J Control Release; 2016 Jun; 231():103-13. PubMed ID: 26941034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study.
    Muller M; Chérel M; Dupré PF; Gouard S; Collet M; Classe JM
    Eur Surg Res; 2011; 46(3):139-47. PubMed ID: 21372578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted delivery of platinum-taxane combination therapy in ovarian cancer.
    Desale SS; Soni KS; Romanova S; Cohen SM; Bronich TK
    J Control Release; 2015 Dec; 220(Pt B):651-9. PubMed ID: 26381902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.